Listing 16.2.4 Demographics and Baseline Characteristics (Safety Population) Treatment Group = Clevidipine __________________________________________________________________________________________________________________________________ SBP Patient Target ID/ NYHA Range Age/ Treatment Weight Height BMI BNP NT-proBNP HF (mmHg) Sex Start/Stop Race Ethnicity (kg) (cm) (kg/m^2) (pg/mL) (pg/mL) Chest X-Ray Score U/L __________________________________________________________________________________________________________________________________ 100001/ 14APR10:10:26/ Black or Not 68.3 170.2 23.6 2080.0 Pleural Effusion IV 180/140 51/ 14APR10:15:05 African Hispanic Female American or Latino Vascular Congestion or Redistribution Cardiomegaly 101002/ 08FEB10:20:42/ Black or Not 77.3 177.8 24.5 1070.0 Pleural Effusion IV 140/100 57/ 08FEB10:22:35 African Hispanic Male American or Latino 101003/ 20FEB10:12:38/ Black or Not 84.1 172.7 28.2 1280.0 *12000.0 No Evidence of II 150/110 57/ 20FEB10:15:15 African Hispanic AHF Male American or Latino Cardiomegaly 101006/ 03JAN11:11:32/ Black or Not 100.9 171.5 34.3 384.0 Vascular II 150/110 44/ 03JAN11:15:08 African Hispanic Congestion or Female American or Latino Redistribution Cardiomegaly 101008/ 06FEB12:21:01/ Black or Not 89.1 165.1 32.7 5000.0 *70000.0 Pleural Effusion III 150/110 61/ 06FEB12:22:15 African Hispanic Female American or Latino Cardiomegaly ______________________________________________________________________________________________________________________________________ _ BMI=Body Mass Index SBP=Systolic Blood Pressure U/L=Upper/Lower Limit. Prefix '*' for BNP and NT-proBNP indicates that the baseline data are missing and first post treatment data are included. Prefix '*' for Chest X-Ray indicates that the baseline X-Ray is missing and X-Ray data within 3 hours post treatment are included. Compound: Clevidipine (TMC-CLV-08-01), SAS Program: L_DEMOG.SAS /Date: 05JUL2012 14:32 (Page 1 of 22) Listing 16.2.4 Demographics and Baseline Characteristics (Safety Population) Treatment Group = Clevidipine __________________________________________________________________________________________________________________________________ SBP Patient Target ID/ NYHA Range Age/ Treatment Weight Height BMI BNP NT-proBNP HF (mmHg) Sex Start/Stop Race Ethnicity (kg) (cm) (kg/m^2) (pg/mL) (pg/mL) Chest X-Ray Score U/L __________________________________________________________________________________________________________________________________ 102001/ 01SEP09:13:39/ Black or Not 77.3 172.7 25.9 25579.0 Acute Pulmonary III 160/120 47/ 01SEP09:15:47 African Hispanic Edema, Male American or Latino Including Interstitial or Alveolar Edema 102004/ 01OCT09:13:08/ White Not 87.7 180.3 27.0 7633.0 Pleural Effusion III 160/120 77/ 01OCT09:16:48 Hispanic Female or Latino Acute Pulmonary Edema, Including Interstitial or Alveolar Edema 102008/ 10DEC09:15:27/ Black or Not 73.0 158.0 29.2 3366.0 31793.0 Pleural Effusion IV 160/120 66/ 10DEC09:17:30 African Hispanic Female American or Latino Acute Pulmonary Edema, Including Interstitial or Alveolar Edema Cardiomegaly 102010/ 26MAR10:11:27/ Black or Not 69.0 157.0 28.0 Pleural Effusion IV 180/140 60/ 26MAR10:13:08 African Hispanic Male American or Latino ______________________________________________________________________________________________________________________________________ BMI=Body Mass Index SBP=Systolic Blood Pressure U/L=Upper/Lower Limit. Prefix '*' for BNP and NT-proBNP indicates that the baseline data are missing and first post treatment data are included. Prefix '*' for Chest X-Ray indicates that the baseline X-Ray is missing and X-Ray data within 3 hours post treatment are included. Compound: Clevidipine (TMC-CLV-08-01), SAS Program: L_DEMOG.SAS /Date: 05JUL2012 14:32 (Page 2 of 22)